Associations between VMAT2 density and serum LDL, HDL levels in Parkinson's disease

Rui Gao,Guangjian Zhang,Xueqi Chen,Aimin Yang,Ming Zhang,Gwenn Smith,Dean Wong,Yun Zhou
2015-01-01
Journal of Nuclear Medicine
Abstract:83 Objectives To explore the association between serum high-density lipoprotein (HDL), and low-density lipoprotein (LDL) and vesicular monoamine transporter 2 (VMAT2) binding in Parkinson’s disease (PD). Methods The VMAT2 measurements using 18F-AV133 PET 80 min post tracer injection, and structural MRI for 22 PD patients and 4 controls were collected from the Parkinson’s Progression Markers Initiative study (PPMI) project. 154 PD and 100 controls with plasma indicators were also included. SPM8 was used for PET alignment, MRI to PET coregistration, and spatial normalization. ROIs were defined on the standard MNI space, and occipital cortex was used as reference to calculate SUVRs. The template ROIs were evaluated by manually ROI drawing in native PET space. The relationship between the clinical features, plasma HDL and LDL, and ROI SUVRs were explored. Results The SUVRs of caudate, anteior- and posterior-putamen in PD were significantly lower (1.92±0.49 vs. 2.79±0.15, 2.34±0.53 vs. 3.19±0.29, and 1.69±0.34 vs. 3.19±0.26, P 0.5). The SUVRs of the above mentioned ROIs were negative correlated to the HDL levels (correlation coefficient Rs: -0.74 to -0.96, P Conclusions This study provided the first evidence of a strong correlation between VMAT2 density and serum LDL, HDL levels in PD. Its role in PD progression will be continuously studied with the ongoing PPMI project. .
What problem does this paper attempt to address?